CN103429592A - 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪 - Google Patents

作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪 Download PDF

Info

Publication number
CN103429592A
CN103429592A CN2011800678029A CN201180067802A CN103429592A CN 103429592 A CN103429592 A CN 103429592A CN 2011800678029 A CN2011800678029 A CN 2011800678029A CN 201180067802 A CN201180067802 A CN 201180067802A CN 103429592 A CN103429592 A CN 103429592A
Authority
CN
China
Prior art keywords
alkyl
amino
imidazo
cyclopropyl
pyrazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800678029A
Other languages
English (en)
Chinese (zh)
Inventor
M·科皮茨
U·克拉尔
R·若泰拉特
D·科泽蒙德
R·博尔曼
B·巴德尔
P·利瑙
G·西迈斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN103429592A publication Critical patent/CN103429592A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2011800678029A 2010-12-17 2011-12-13 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪 Pending CN103429592A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10195699 2010-12-17
EP10195635 2010-12-17
EP10195699.3 2010-12-17
EP10195635.7 2010-12-17
EP11170163.7 2011-06-16
EP11170158 2011-06-16
EP11170163 2011-06-16
EP11170158.7 2011-06-16
PCT/EP2011/072591 WO2012080236A1 (en) 2010-12-17 2011-12-13 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Publications (1)

Publication Number Publication Date
CN103429592A true CN103429592A (zh) 2013-12-04

Family

ID=45218758

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800678029A Pending CN103429592A (zh) 2010-12-17 2011-12-13 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪

Country Status (6)

Country Link
US (1) US20140135319A1 (enExample)
EP (1) EP2651945A1 (enExample)
JP (1) JP2013545779A (enExample)
CN (1) CN103429592A (enExample)
CA (1) CA2821819A1 (enExample)
WO (1) WO2012080236A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100852A (ja) * 1984-09-28 1985-06-04 Hitachi Ltd 情報伝送方法
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
EP2920181B1 (en) 2012-11-16 2019-01-09 University Health Network Pyrazolopyrimidine compounds
EP3027601B1 (en) 2013-07-31 2017-10-25 Gilead Sciences, Inc. Syk inhibitors
EA029372B1 (ru) * 2013-11-15 2018-03-30 Юниверсити Хелс Нетуорк Пиразолопиримидиновые соединения
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
CN107567503B (zh) 2015-04-17 2022-03-22 荷兰转化研究中心有限责任公司 用于ttk抑制剂化疗的预后生物标记
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
CN109414410B (zh) 2016-04-22 2022-08-12 因赛特公司 Lsd1抑制剂的制剂
TW201841916A (zh) 2017-04-12 2018-12-01 美商麥珍塔治療學股份有限公司 芳香烴受體拮抗劑及其用途
WO2019089826A1 (en) * 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
PL3792260T3 (pl) * 2018-05-08 2024-12-02 Nippon Shinyaku Co., Ltd. Związki azabenzimidazolowe i środki farmaceutyczne
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
US20210379033A1 (en) * 2018-10-17 2021-12-09 Magenta Therapeutics Inc. Methods of treating cancer with aryl hydrocarbon receptor antagonists
WO2021095801A1 (ja) 2019-11-13 2021-05-20 日本新薬株式会社 アザベンゾイミダゾール化合物及び医薬

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220189A1 (en) * 2003-02-20 2004-11-04 Sugen, Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors
US20050009832A1 (en) * 2003-02-20 2005-01-13 Sugen, Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
CN1694706A (zh) * 2002-09-23 2005-11-09 先灵公司 用作依赖细胞周期蛋白的激酶抑制剂的新的咪唑并吡嗪
CN1694886A (zh) * 2002-09-23 2005-11-09 先灵公司 作为周期素依赖性激酶抑制剂的咪唑并吡嗪
WO2007056468A1 (en) * 2005-11-10 2007-05-18 Schering Corporation Methods for inhibiting protein kinases
CN101300233A (zh) * 2005-09-09 2008-11-05 先灵公司 氮杂稠合的细胞周期蛋白依赖性激酶抑制剂
CN101331135A (zh) * 2005-11-10 2008-12-24 先灵公司 作为细胞周期蛋白依赖激酶抑制剂的新型咪唑并吡嗪
CN101370811A (zh) * 2005-11-10 2009-02-18 先灵公司 作为蛋白激酶抑制剂的咪唑并吡嗪化合物
WO2009024585A2 (en) * 2007-08-21 2009-02-26 Biofocus Dpi Limited Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis
WO2010124826A1 (en) * 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
WO2011013729A1 (ja) * 2009-07-30 2011-02-03 オンコセラピー・サイエンス株式会社 Ｔｔｋ阻害作用を有する縮合イミダゾール誘導体
CN102971321A (zh) * 2010-03-18 2013-03-13 拜耳知识产权有限责任公司 咪唑并吡嗪
CN103038235A (zh) * 2010-06-01 2013-04-10 拜耳知识产权有限责任公司 取代的咪唑并吡嗪

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
MX2008015747A (es) 2006-06-06 2008-12-19 Schering Corp Imidazopirazinas como inhibidores de la proteina quinasa.
EP2471529A3 (en) * 2006-09-05 2012-10-10 Emory University Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof
AR063581A1 (es) 2006-11-08 2009-02-04 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa
JP2010536841A (ja) * 2007-08-23 2010-12-02 アストラゼネカ アクチボラグ 増殖性疾患治療のためのｔｔｋ／ｍｐｓ１阻害剤としての２−アニリノプリン−８−オン類
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
JP5824065B2 (ja) * 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
EP2651950A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2651947B1 (en) * 2010-12-17 2014-12-10 Bayer Intellectual Property GmbH 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1694706A (zh) * 2002-09-23 2005-11-09 先灵公司 用作依赖细胞周期蛋白的激酶抑制剂的新的咪唑并吡嗪
CN1694886A (zh) * 2002-09-23 2005-11-09 先灵公司 作为周期素依赖性激酶抑制剂的咪唑并吡嗪
US20050009832A1 (en) * 2003-02-20 2005-01-13 Sugen, Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US20040220189A1 (en) * 2003-02-20 2004-11-04 Sugen, Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors
CN101300233A (zh) * 2005-09-09 2008-11-05 先灵公司 氮杂稠合的细胞周期蛋白依赖性激酶抑制剂
CN101331135A (zh) * 2005-11-10 2008-12-24 先灵公司 作为细胞周期蛋白依赖激酶抑制剂的新型咪唑并吡嗪
WO2007056468A1 (en) * 2005-11-10 2007-05-18 Schering Corporation Methods for inhibiting protein kinases
CN101370811A (zh) * 2005-11-10 2009-02-18 先灵公司 作为蛋白激酶抑制剂的咪唑并吡嗪化合物
WO2009024585A2 (en) * 2007-08-21 2009-02-26 Biofocus Dpi Limited Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis
WO2010124826A1 (en) * 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
WO2011013729A1 (ja) * 2009-07-30 2011-02-03 オンコセラピー・サイエンス株式会社 Ｔｔｋ阻害作用を有する縮合イミダゾール誘導体
CN102971321A (zh) * 2010-03-18 2013-03-13 拜耳知识产权有限责任公司 咪唑并吡嗪
CN103038235A (zh) * 2010-06-01 2013-04-10 拜耳知识产权有限责任公司 取代的咪唑并吡嗪

Also Published As

Publication number Publication date
EP2651945A1 (en) 2013-10-23
WO2012080236A1 (en) 2012-06-21
JP2013545779A (ja) 2013-12-26
CA2821819A1 (en) 2012-06-21
US20140135319A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
CN103443100B (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的取代的6-咪唑并吡嗪
CN102413831B (zh) 取代的咪唑并喹喔啉
CN102858768B (zh) 取代三唑并吡啶
CN102971321B (zh) 咪唑并吡嗪
CN103687858B (zh) 作为mknk1激酶抑制剂的氨基取代的咪唑并哒嗪
CN103370318B (zh) 取代的咪唑并哒嗪
JP5822944B2 (ja) 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン
CN103429592A (zh) 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪
CN103958515B (zh) 氨基取代的咪唑并哒嗪
CN103038235B (zh) 取代的咪唑并吡嗪
CN103764656A (zh) 杂环基氨基咪唑并哒嗪
CN102596932A (zh) 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
EP2651950A1 (en) 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN104114559A (zh) 氨基取代的咪唑并哒嗪
CN103415518A (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪
CN103403006B (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪
CN104284896B (zh) 取代的咪唑并哒嗪
CN103649087B (zh) 取代的咪唑并吡啶及其中间体
HK1187622B (en) 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103649087A (zh) 取代的咪唑并吡啶及其中间体
HK1180333B (en) Substituted triazolopyridines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131204